EE84 Cost-Effectiveness of Pembrolizumab Plus Nab-paclitaxel in Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (TNBC) Whose Tumors Expressed Pd-L1 (CPS ≥10) in Colombia
Abstract
Authors
J. Urrego-Reyes C. Lopez C. Marrugo A. J.S. Velasco P. Singla S. Gotarkar M. Huang A. Haiderali